[an error occurred while processing this directive] | [an error occurred while processing this directive]
Different fractionation schedules of radiotherapy in preoperative concurrent chemoradiotherapy for thoracic esophageal cancer:a clinical study
Lyu Jiahua, Liu Tao, Li Tao, Li Fang, Wang Junchao, Yang Chuan, Zhang Jun, Wang Jie, Lang Jinyi
Sichuan Cancer Hospital Institute/Sichuan Cancer Center/School of Medicine, University of Electronic Science and Technology of China,Chengdu 610041,China (Lyu JH,Li T,Li F,Wang JC,Yang C,Zhang J,Wang J,Lang JY); Department of Oncology,Ya′an People′ Hospital,Ya′an 625000,China (Liu Tao)
AbstractObjective To investigate the clinical efficacy and safety of preoperative hypofractionated and conventionally-fractionated chemoradiotherapy for thoracic esophageal cancer. Methods A total of 86 patients with thoracic esophageal cancer receiving chemoradiotherpy in Sichuan Cancer Hospital between 2002 and 2011 were enrolled and randomized into the preoperative hypofractionated chemoradiotherapy group (group A, n=41,30 Gy in 10 fractions for 2 weeks) and conventionally-fractionated chemoradiotherapy group (group B, n=45,40 Gy in 20 fractions for 4 weeks). Surgery was performed at 2-6 weeks after chemoradiotherapy. The probability of patients’ survival was estimated by Kaplan-Meier method and analyzed by log-rank test. Results In groups A and B, the pathological downstaging rates were 68% and 56%(P=0.270), the R0 resection rates were 95% and 89%(P=0.437) and the pCR rates of 32% and 24%(P=0.480).The 1-,3-and 5-year overall survival (OS) rates were 78% and 69%,44% and 44%,29% and 33%(P=0.114,0.223,0.289), and the progression-free survival (PFS) rates were 71% and 62%,39% and 38%,24% and 29%(P=0.211,0.689,0.331), respectively. The incidence rate of chemoradiothery-and surgery-related adverse events did not differ between two groups (P=0.089-0.872).The average length of hospital stay, radiotherapy cost and preoperative treatment costs in group A were significantly less compared with those in group B (P=0.000,0.000,0.000). Conclusions Both preoperative hypofractionated and conventionally-fractionated chemoradiotherapy can be used as the regimen of preoperative chemoradiotherapy in patients with resectable thoracic esophageal carcinoma. Compared with conventionally-fractionated chemoradiotherapy, preoperative hypofractionated chemoradiotherapy has shorter treatment cycle, shorter length of hospital stay and lower radiotherapy cost, which is more easily accepted by patients.
Fund:Basic project of Science and Technology Department of Sichuan Province (2017JY0307)
Corresponding Authors:
Li Tao,Email:litaoxmf@126.com
Cite this article:
Lyu Jiahua,Liu Tao,Li Tao et al. Different fractionation schedules of radiotherapy in preoperative concurrent chemoradiotherapy for thoracic esophageal cancer:a clinical study[J]. Chinese Journal of Radiation Oncology, 2018, 27(6): 576-580.
Lyu Jiahua,Liu Tao,Li Tao et al. Different fractionation schedules of radiotherapy in preoperative concurrent chemoradiotherapy for thoracic esophageal cancer:a clinical study[J]. Chinese Journal of Radiation Oncology, 2018, 27(6): 576-580.
[1] Li SL,Liu HT,Diao CY,et al. Prognosis of surgery combined with different adjuvant therapies in esophageal cancer treatment:a network meta-analysis[J].Oncotarget,2017,8(22):36339-36353.DOI:10.18632/oncotarget.16193. [2] Kim KH,Chang JS,Cha JH,et al. Optimal adjuvant treatment for curatively resected thoracic esophageal squamous cell carcinoma:a radiotherapy perspective[J].Cancer Res Treat,2017,49(1):168-177.DOI:10.4143/crt.2016.142. [3] Li LL,Zhao LH,Lin BC,et al. Adjuvant therapeutic modalities following three-field lymph node dissection for stage Ⅱ/Ⅲ esophageal squamous cell carcinoma[J].J Cancer,2017,8(11):2051-2059.DOI:10.7150/jca.18981. [4] Kleinberg LR,Catalano P,Forastiere AA,et al. Eastern Cooperative Oncology Group (E1201) randomized phase Ⅱ trial of neoadjuvant preoperative paclitaxel/cisplatin/radiotherapy (RT) or irinotecan/cisplatin/RT in esophageal adenocarcinoma:long term outcome and implications for trial design[J].Int J Radiat Oncol Biol Phys,2016,94(4):738-746.DOI:10.1016/j.ijrobp.2015.12.009. [5] Wang QF,Zhang WC,Liu X,et al. Prognosis of esophageal squamous cell carcinoma patients with preoperative radiotherapy:comparison of different cancer staging systems[J].Thorac Cancer,2014,5(3):204-210.DOI:10.1111/1759-7714.12079. [6] Chen WQ,Zheng RS,Baade PD,et al. Cancer statistics in China,2015[J].CA Cancer J Clin,2016,66(2):115-132.DOI:10.3322/caac.21338. [7] Van Heijl M,Van Lanschot JJB,Koppert LB,et al. Neoadjuvant chemoradiation followed by surgery versus surgery alone for patients with adenocarcinoma or squamous cell carcinoma of the esophagus (CROSS)[J].BMC Surg,2008,8:21.DOI:10.1186/1471-2482-8-21. [8] Shapiro J,Van Lanschot JJB,Hulshof MCCM,et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS):long-term results of a randomised controlled trial[J].Lancet Oncol,2015,16(9):1090-1098.DOI:10.1016/S1470-2045(15)00040-6. [9] Yang H,Fu J,Liu M,et al. A phase Ⅲ clinical trial of neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus[J].Arq Gastroenterol,2014,50(2):101-106. [10] 陈秀勇,郑晓,郭金水,等.肺癌、食管癌及贲门癌术前大剂量短程放疗的效应[J].实用肿瘤杂志,1992,7(1):34-35.DOI:10.13267/j.cnki.syzlzz.1992.01.021. Chen XY,Zheng X,Guo JS,et al. Effect of high-dose short-term radiotherapy on lung cancer,esophageal and cardiac cancer[J].J Practical Oncol,1992,7(1):34-35.DOI:10.13267/j.cnki.syzlzz.1992.01.021. [11] 陈久成,于金明,张百江,等.食管癌术前大剂量短程放疗的临床研究[J].齐鲁肿瘤杂志,1998,5(1):43-46.DOI:10.16073/j.cnki.cjcpt.1998.01.026. Chen JC,Yu JM,Zhang BJ,et al. Large dose and short course preoperative radiotherapy and surgical treatment in the esophageal cancer[J].J Qilu Oncol,1998,5(1):43-46.DOI:10.16073/j.cnki.cjcpt.1998.01.026. [12] 王捷,何玲,李涛,等.食管癌术前大分割放疗远期疗效分析[J].中国肿瘤临床与康复,2001,8(4):82-83.DOI:10.13455/j.cnki.cjcor.2001.04.050. Wang J,He L,Li T,et al. Long-term results of preoperative hypofractionated radiotherapy for esophageal carcinoma[J].Chin J Clin Oncol Rehabil,2001,8(4):82-83.DOI:10.13455/j.cnki.cjcor.2001.04.050. [13] Ma JB,Wei L,Chen EC,et al. Moderately hypofractionated conformal radiation treatment of thoracic esophageal carcinoma[J].Asian Pac J Cancer Prev,2012,13(8):4163-4167.DOI:10.7314/APJCP.2012.13.8.4163. [14] Ma ZQ,Zhang Y,Chen XF,et al. Analysis of different fractionations of three-dimensional conformable radiotherapy for esophageal cancer[J].Int J Clin Exp Med,2015,8(7):11139-11145.
2018, Vol. 27 
